AstraZeneca Pharma India Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
AstraZeneca Pharma India Fair Value Forecast for 2023 - 2025 - 2030
In the last year, AstraZeneca Pharma India's Price has gone down from Rp2738.08 to Rp0.00 – a 100.00% drop. Next year, analysts are expecting Fair Value to reach Rp0.00 – an increase of 100.00%. Over the next five years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500488 Stock Forecast | Abbott India | Outperform |
18
|
Rp26.42k | Buy/Sell | Rp24.75k | 11.68% |
| 500660 Stock Forecast | GlaxoSmithKline Pharmaceutical... | Hold |
18
|
Rp2.09k | Buy/Sell | Rp1.78k | 1.10% |
| PFIZER Stock Forecast | Pfizer | Outperform |
18
|
Rp4.26k | Buy/Sell | Rp4.53k | 15.92% |
| 500674 Stock Forecast | Sanofi India | Outperform |
18
|
Rp8.32k | Buy/Sell | Rp8.61k | 10.16% |
| 500126 Stock Forecast | Procter & Gamble Health | - |
17
|
Rp4.92k | Buy/Sell | Rp5.62k | -100.00% |
AstraZeneca Pharma India Revenue Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca Pharma India's Revenue has grown from Rp8.32B to Rp10.03B – a 20.58% increase. In the next year, 0 analysts estimate that AstraZeneca Pharma India's Revenue will decrease by 5.48%, reaching Rp9.48B. According to professional forecasts, in 2030, AstraZeneca Pharma India's Revenue will decrease by 9.50%, reaching Rp9.08B.
.jpg)
AstraZeneca Pharma India Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca Pharma India's Dividend per Share has grown by 1500.00%, rising from Rp1.00 to Rp16.00. According to 0 analysts, AstraZeneca Pharma India's Dividend per Share will fall by 55.83% in the next year, reaching Rp7.07. Professionals believe that By 2030, AstraZeneca Pharma India's Dividend per Share will fall to Rp9.63 – a 39.83% decrease from its current value.
AstraZeneca Pharma India EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca Pharma India's EBITDA has grown, rising from Rp1.18B to Rp1.61B – a growth of 36.74%. In the next year, analysts believe that EBITDA will reach Rp1.62B – an increase of 0.21%. By 2030, professionals predict that AstraZeneca Pharma India's EBITDA will decrease by 6.15%, to Rp1.51B.
AstraZeneca Pharma India EBIT Forecast for 2023 - 2025 - 2030
AstraZeneca Pharma India's EBIT has grown In the last three years, rising from Rp1.03B to Rp1.49B – a growth of 45.14%. In the next year, analysts believe that EBIT will reach Rp1.50B – an increase of 0.81%. In 2030, the professionals' prediction is that 506820's EBIT will decrease by 6.16%, reaching Rp1.40B.
AstraZeneca Pharma India EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, AstraZeneca Pharma India's EPS has gone down from Rp28.68 to Rp0.00 – a 100.00% drop. Next year, analysts are expecting EPS to reach Rp0.00 – an increase of 100.00%. Over the next five years, the forecast is for EPS to grow by 100.00%.
Site Navigation
.jpg)